The analysis of second-trimester triple screening for Down syndrome in Chinese normal singleton pregnancies

被引:9
作者
Wan, Xiaohua [1 ]
Wen, Jiangping [1 ]
Song, Xin [1 ]
Guo, Yongjun [1 ]
Liu, Xiangyi [1 ]
Yang, Benshan [1 ]
Lu, Xinxin [1 ]
机构
[1] Capital Med Univ, Beijing Tongren Hosp, Dept Clin Lab, Beijing 100730, Peoples R China
关键词
Second-trimester; triple screening; Down syndrome; alpha fetoprotein; human chorionic gonadotropin; unconjugated estriol; HUMAN CHORIONIC-GONADOTROPIN; SERUM ALPHA-FETOPROTEIN; MATERNAL SERUM; TECHNICAL STANDARDS; WEIGHT-CORRECTION; GUIDELINES; ANALYZER; MEDIANS; MARKERS;
D O I
10.3109/00365513.2012.729858
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background and objectives. The study aimed to compare the a fetoprotein (AFP), total beta-human chorionic gonadotropin (hCG), and unconjugated estriol (uE3) levels in the second-trimester triple screening for Down syndrome with different regions, and to analyse the related factors that influenced the screening performance. Materials and methods. The study was conducted between February 2007 and November 2010 in Beijing Tongren Hospital, P. R. China. Data derived from 7,647 normal singleton pregnancies between 14 and 21 weeks of gestation were examined. The regressed median values in different gestational ages were compared with earlier published data from other regions. The distribution of median values and multiples of median (MoM) of AFP, hCG and uE3 according to maternal age and weight in normal pregnancies were described. Statistic parameters for AFP, hCG, and uE3 (based on log(10) MoM values) were compared with earlier published data from other studies. Results. There were significantly increasing trends for AFP (p < 0.001) and uE3 (p < 0.001), and a significantly decreasing trend for hCG (p < 0.001) in the second trimester. There were significantly decreasing trends with increasing maternal weight for all the markers and their MoMs (p < 0.001). The distribution of the log(10) MoM marker values were Gaussian for the three parameters. Conclusions. Ethnic and laboratory variance should be taken into account in the second trimester triple screening for Down syndrome. The parameters of maternal serum markers should be calculated using local data, and the algorithm modified to match the screening achievable for the local population.
引用
收藏
页码:642 / 647
页数:6
相关论文
共 24 条
  • [1] Second trimester screening for Down's syndrome: 7 years experience
    Beaman, JM
    Goldie, DJ
    [J]. JOURNAL OF MEDICAL SCREENING, 2001, 8 (03) : 128 - 131
  • [2] Benn PA, 1997, CLIN CHEM, V43, P333
  • [3] Advances in prenatal screening for Down syndrome: I. General principles and second trimester testing
    Benn, PA
    [J]. CLINICA CHIMICA ACTA, 2002, 323 (1-2) : 1 - 16
  • [4] Evaluation of effect of analytical imprecision in maternal serum screening for Down's syndrome
    Benn, PA
    Collins, R
    [J]. ANNALS OF CLINICAL BIOCHEMISTRY, 2001, 38 : 28 - 36
  • [5] Reproducibility of risk figures in 2nd-trimester maternal serum screening for Down syndrome: Comparison of 2 laboratories
    Benn, Peter A.
    Makowski, Gregory S.
    Egan, James F. X.
    Wright, Dave
    [J]. CLINICAL CHEMISTRY, 2006, 52 (11) : 2087 - 2094
  • [6] PROSPECTIVE EVALUATION OF MATERNAL SERUM HUMAN CHORIONIC-GONADOTROPIN LEVELS IN 3428 PREGNANCIES
    BOGART, MH
    JONES, OW
    FELDER, RA
    BEST, RG
    BRADLEY, L
    BUTTS, W
    CRANDALL, B
    MACMAHON, W
    WIANS, FH
    LOEH, PV
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1991, 165 (03) : 663 - 667
  • [7] Prenatal screening for Down syndrome - Current and future methods
    Canick, JA
    Saller, DN
    Lambert-Messerlian, GM
    [J]. CLINICS IN LABORATORY MEDICINE, 2003, 23 (02) : 395 - +
  • [8] CRANDALL BF, 1983, CLIN CHEM, V29, P531
  • [9] Cuckle H, 1998, LANCET, V352, P1144, DOI 10.1016/S0140-6736(98)00030-0
  • [10] Outcome validation of the Beckman Coulter Access analyzer in a second-trimester Down syndrome serum screening application
    MacRae, AR
    Gardner, HA
    Allen, LC
    Tokmakejian, S
    Lepage, N
    [J]. CLINICAL CHEMISTRY, 2003, 49 (01) : 69 - 76